The effect of Bepotastine besilate OD tablet for Japanese cedar pollinosis in an artificial exposure chamber(OHIO Chamber).

The effect of Bepotastine besilate OD tablet for Japanese cedar pollinosis in an artificial exposure chamber(OHIO Chamber). - The effect of Bepotastine besilate OD tablet for Japanese cedar pollinosis in an artificial exposure chamber(OHIO Chamber).

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000008249

Enrollment

Registered

2012-06-26

Start date

2012-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Japanese cedar Pollinosis

Interventions

Bepotastine besilate OD tablets administered to 35 subjects twice daily on the Japanese cedar pollen exposure day(30 minutes after the start of exposure and night). The next day and the following day

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)CAP-RAST score against Japanese cedar pollen over class 2 within the last 3 years. 2)Have experience with cedar pollen exposure in the OHIO Chamber in the past, patients with nasal symptoms. 3)Patients who are considered eligible medical examination results investigator doctors. 4)Written informed consent is required.

Exclusion criteria

Exclusion criteria: 1)Some patients with mucosal lesion of the nose and eyes. 2)Patients with severe perennial allergic rhinitis or requiring treatment. 3)Patients who received steroid injections within 6 months. 4)Patients with respiratory disease such as asthma. 5)Patients with past history of anaphylaxis. 6)Patients who have the hypersensitivity to study drug. 7)Pregnancy,breast-feeding woman,potential pregnancy,patients who wish to become pregnant during this study. 8)Patients who were judged to be unsuitable for patient enrollment by their doctor (Patients who have undergone nasal operation or patients who have receiving immunotherapy).

Design outcomes

Primary

Measure	Time frame
Symptoms score (Nasal)	—

Secondary

Measure	Time frame
1)Nasal secretion volume 2)Number of sneezing 3)Occurrence time of first nasal symptom 4)Digit Cancellation test	—

Countries

Japan

Contacts

Public ContactSatoko Shimizu

Tokyo Reserch Center of Clinical Pharmacology co.,ltd. Clinical Trial Operations Support Section,Customer Relations Dept.

s-shimizu@trcp.co.jp

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026